Best Read PBM News Stories in 2022
Among the most-read stories about PBMs include Transcarent and Prescryptive Health teaming up for employer pharmacy; Kroger Health ending agreement with Express Scripts; Mark Cuban Cost Plus Drugs teaming up with EmsanaRx and Vivio Health; and Abarca Health takes on a challenging implementation.
Transcarent and Prescryptive Health Partner for Integrated Pharmacy
Transcarent has teamed up with Prescryptive Health to provide self-insured employers and their employees access to Prescryptive’s network of more than 60,000 retail, home delivery and specialty pharmacies.
Kroger Health to Terminate Express Scripts Agreement
Kroger Health, the healthcare division of The Kroger Co., notified Express Scripts of its intention to terminate their pharmacy provider agreement for commercial customers.
Mark Cuban’s Pharmacy and Vivio Team up to Manage Specialty Drugs
Vivio Health, a specialty drug management company, has formed a relationship with Mark Cuban Cost Plus Drug Company to access specialty drugs from the online pharmacy.
EmsanaRx and Mark Cuban’s Pharmacy Offer New Program
The EmsanaRx Plus program is connecting employers to the discounted drugs offered through Mark Cuban Cost Plus Drug Company. The program will be available beginning March 1, 2023.
How Long Should a PBM Implementation Take?
When Abarca Health took over as the full-service PBM for Vital, the Medicaid program managed by the Puerto Rico Health Insurance Administration, it faced a challenge. The PBM needed to implement the program in just 10 days.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More
